PSMA is a protein that is used as a validated biomarker of prostate cancer, is expressed on the surface of prostate cancer cells and on blood vessels supplying other solid tumors.
PSMA ADC combines a fully human monoclonal antibody selectively targeted to PSMA linked to a chemotherapeutic drug.
The aim of the study was to assess PSMA ADC’s safety and tolerability, as well as evaluate pharmacodynamics, changes in tumor burden and in PSA and CTC values compared to baseline.
Results showed the most common clinical adverse event to be fatigue, and the most common laboratory adverse events to be reversible neutropenia and elevations in liver enzymes.
Pancreatic toxicity was not observed with PSMA ADC in anypatient save one, and PSMA ADC exhibited dose-proportional pharmacokinetics. No antibodies to PSMA ADC were observed in any subject.
Progenics’ senior vice president of Medical Affairs and Clinical Research Robert Israel said treatment with PSMA ADC in the ongoing study resulted in meaningful reductions in two commonly used biomarkers of prostate cancer progression and cancer-related bone pain and this raises hopes of exploring the potential utility of this novel agent.